A5048013732- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Screening and Detection
- Plant Micronutrient Interactions and Effects
- Health and Medical Research Impacts
- Pancreatic and Hepatic Oncology Research
- Aluminum toxicity and tolerance in plants and animals
- Phagocytosis and Immune Regulation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- SARS-CoV-2 and COVID-19 Research
- Health Systems, Economic Evaluations, Quality of Life
- Prostate Cancer Diagnosis and Treatment
- Plant Stress Responses and Tolerance
- Gastric Cancer Management and Outcomes
- Cancer, Lipids, and Metabolism
- Intestinal and Peritoneal Adhesions
- PI3K/AKT/mTOR signaling in cancer
- Ethics in Clinical Research
- HER2/EGFR in Cancer Research
- Heavy Metals in Plants
- Science, Research, and Medicine
- COVID-19 Clinical Research Studies
Walter and Eliza Hall Institute of Medical Research
2018-2025
The University of Melbourne
2014-2024
Parks Victoria
2024
Peter MacCallum Cancer Centre
2023
Monash University
2021
Murdoch Children's Research Institute
2018
Genomic alterations in DNA damage response (DDR) genes are common metastatic castration-resistant prostate cancer (mCRPC). Understanding how these genomic events impact prognosis and/or treatment is vital for optimising clinical outcomes.
Abstract Background Dysregulated programmed cell death plays a key role in IBD pathogenesis, with clinical trials exploring anti-necroptotic therapies (1,2). While apoptosis and necroptosis are well-studied murine colitis models, their prevalence, mechanisms, therapeutic relevance human remains unclear. We examined pathways patients on advanced therapies, uncovering unique signalling mechanisms that could inform future treatments. Methods Over 900 paired intestinal biopsies were analysed...
Tumor tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the PTEN-PI3K-AKT pathway. However, identifying CNVs plasma cell-free DNA (cfDNA) has proven to be challenging. With emerging data supporting Akt inhibition PTEN-deficient mCRPC, we profiled pathway aberrations patients with mCRPC using a novel cfDNA assay optimized for CNV detection.
ABSTRACT Inflammatory bowel disease (IBD) is a chronic condition caused by altered cytokine signaling, maladaptive immunity, dysbiosis, and intestinal barrier dysfunction. Patients with IBD receive therapy to correct these imbalances achieve remission. However, most patients relapse, suggesting that pathological mechanisms persist during Here, we show excess epithelial cell death an underlying feature of arises in remission on advanced therapy. Mechanistically, nascent inflammation...
<italic>Noccaea caerulescens</italic> can accumulate more than 2% Zn in the leaves without showing any outwards signs of toxicity however a myriad elemental and metabolite changes occur at these concentrations.
Background and Aim Polyethylene glycol (PEG) is the gold standard for fecal disimpaction in constipation. A regimen of PEG combined with stimulant laxative sodium picosulphate (SPS) produced chronically constipated children community, but it unknown if effective more severe To determine stool output effect a SPS on fecaloma constipation impaction. Methods Children symptoms duration ≥2 years, palpable fecaloma, enlarged rectum X‐ray (rectal: pelvic ratio > 0.6) were recruited from tertiary...
As potent systemic therapies transition earlier in the prostate cancer disease course, molecular biomarkers are needed to guide optimal treatment selection for metastatic hormone-sensitive (mHSPC). The value of whole blood RNA detect candidate mHSPC remains largely undefined.In this cohort study, we used a previously optimised reverse transcription polymerase chain reaction assay assess prognostic utility [measured by seven-month undetectable prostate-specific antigen (PSA) and time...
Abstract Background The androgen receptor (AR) pathway‐associated gene nuclear coactivator 2 ( NCOA2 ) has an established oncogenic role in early prostate cancer and likewise is a driver of metastatic disease castration‐resistant cancer. However, its significance as biomarker (mCRPC), both alone conjunction with co‐occurring AR alterations using liquid biopsy approach not been investigated. Methods Ninety‐one patients were included this study, n = 68 receiving pathway inhibitor 23 taxane...
Abstract [177Lu]Lu-PSMA-617 (LuPSMA) radionuclide therapy improves overall survival in mCRPC, and was recently approved by the FDA. Nevertheless, owing to heterogeneous nature of responses LuPSMA can be variable, resistance is inevitable. As a result, biomarkers linked clinical outcome with are urgently required. Using plasma ctDNA, we present first comprehensive genomic analysis prospective cohort mCRPC patients treated LuPSMA. Targeted sequencing 78 genes performed on baseline matched...
Abstract Purpose The COVID PROFILE cohort is a longitudinal clinical study based in Victoria Australia, which was established to understand immunity SARS-CoV-2 low transmission population setting and identify immunological markers of long-term immune-dysregulation after both infection vaccination. Additionally, this as biobank resource for researchers address other health-related questions. Participants We enrolled 178 adult community members, including household contacts, who had either...
The restrictive eligibility criteria of therapy-focused cancer clinical trials can limit the external validity results. characteristics and survival outcomes patients enrolled in stand-alone biomarker studies have yet to be explored. We examined a series stage II III colorectal (CRC) broader patient population from which study cohorts were recruited.We three distinct trial scenarios: retrospective cohort (RCS) where archival tissue samples analyzed, prospective observational (POS) blood...
For patients with metastatic colorectal cancer (mCRC), epidermal growth factor receptor (EGFR) inhibitors are limited to RAS wild-type tumours. Not all will benefit from treatment and better predictive biomarkers needed. Here we investigated the prognostic impact of EGFR ligands amphiregulin (AREG) epiregulin (EREG). Expression levels were assessed by immunohistochemistry on 99 KRAS AREG EREG positivity was seen in 49% 50% cases, respectively. No difference expression observed primary tumour...
150 Background: With the evolving use of targeted therapies exploiting genomic vulnerabilities in mCRPC, screening patients for sensitizing alterations is increasing relevance. However, influence age on detection relevant incompletely understood. In this study, we compared cell-free DNA (cfDNA) profiles younger (age <70) versus older ≥70) men with mCRPC and assessed relative prognostic impact common alterations. Methods: A next-generation sequencing-based Predicine cfDNA assay was used to...
153 Background: The prognostic significance of DDR alterations in mCRPC remains unclear, with conflicting data from prior reports. Whether are predictive outcomes therapeutic agents other than PARP inhibitors is also poorly understood. With increasing use molecular profiling mCRPC, understanding the full and utility plasma paramount. Methods: A next-generation sequencing Predicine liquid biopsy assay was used to profile cfDNA germline DNA 407 patients (pts) two independent international...
159 Background: Tumour tissue from metastatic castration-resistant prostate cancer (mCRPC) harbors frequent copy number variations (CNVs) in the phosphatidylinositol-3-kinase (PI3K)/Akt-signaling pathway. However, identifying CNVs plasma cell-free DNA (cfDNA) has proven challenging. With emerging data supporting Akt inhibition PTEN-deficient mCRPC, cfDNA assays for robustly PI3K/Akt pathway aberrations including are urgently required. Methods: In this multi-institutional prospective...